Adamas Pharmaceuticals (NASDAQ:ADMS) – Stock analysts at Leerink Swann issued their Q1 2018 earnings per share estimates for Adamas Pharmaceuticals in a note issued to investors on Wednesday, April 4th. Leerink Swann analyst G. Porges expects that the specialty pharmaceutical company will earn ($1.41) per share for the quarter. Leerink Swann has a “Outperform” rating and a $31.00 price objective on the stock. Leerink Swann also issued estimates for Adamas Pharmaceuticals’ Q2 2018 earnings at ($1.50) EPS, Q3 2018 earnings at ($1.47) EPS, Q4 2018 earnings at ($1.47) EPS, FY2018 earnings at ($5.81) EPS, FY2019 earnings at ($4.77) EPS, FY2020 earnings at ($1.75) EPS, FY2021 earnings at $1.27 EPS and FY2022 earnings at $4.03 EPS.
A number of other research firms have also recently weighed in on ADMS. BidaskClub upgraded shares of Adamas Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, January 25th. Needham & Company LLC set a $40.00 target price on shares of Adamas Pharmaceuticals and gave the company a “buy” rating in a research note on Sunday, February 25th. ValuEngine upgraded shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Zacks Investment Research upgraded shares of Adamas Pharmaceuticals from a “hold” rating to a “buy” rating and set a $40.00 target price on the stock in a research note on Wednesday, January 3rd. Finally, Piper Jaffray set a $52.00 target price on shares of Adamas Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, December 19th. Two research analysts have rated the stock with a sell rating and twelve have issued a buy rating to the company’s stock. Adamas Pharmaceuticals presently has an average rating of “Buy” and an average target price of $42.89.
Shares of ADMS stock opened at $22.94 on Friday. Adamas Pharmaceuticals has a 52-week low of $13.50 and a 52-week high of $44.00. The company has a quick ratio of 10.69, a current ratio of 10.79 and a debt-to-equity ratio of 1.55. The stock has a market capitalization of $647.39, a price-to-earnings ratio of -5.78 and a beta of 1.59.
Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings data on Thursday, February 22nd. The specialty pharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.18) by ($0.09). The business had revenue of $0.57 million for the quarter, compared to analyst estimates of $0.84 million. During the same period last year, the firm earned ($0.68) earnings per share. The business’s quarterly revenue was up 1435.1% compared to the same quarter last year.
Several hedge funds have recently made changes to their positions in the stock. Alps Advisors Inc. lifted its stake in shares of Adamas Pharmaceuticals by 13.8% during the 4th quarter. Alps Advisors Inc. now owns 25,241 shares of the specialty pharmaceutical company’s stock valued at $855,000 after buying an additional 3,069 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its stake in shares of Adamas Pharmaceuticals by 11.7% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 30,690 shares of the specialty pharmaceutical company’s stock valued at $1,041,000 after buying an additional 3,218 shares in the last quarter. EAM Investors LLC lifted its stake in shares of Adamas Pharmaceuticals by 5.7% during the 4th quarter. EAM Investors LLC now owns 89,585 shares of the specialty pharmaceutical company’s stock valued at $3,036,000 after buying an additional 4,792 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of Adamas Pharmaceuticals during the 3rd quarter valued at approximately $110,000. Finally, Granite Springs Asset Management LLC purchased a new stake in shares of Adamas Pharmaceuticals during the 4th quarter valued at approximately $207,000. Institutional investors own 77.25% of the company’s stock.
In related news, CEO Gregory T. Went sold 4,541 shares of the company’s stock in a transaction that occurred on Wednesday, March 21st. The shares were sold at an average price of $25.75, for a total transaction of $116,930.75. Following the sale, the chief executive officer now directly owns 182,610 shares in the company, valued at approximately $4,702,207.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Rajiv Patni sold 1,252 shares of the company’s stock in a transaction that occurred on Wednesday, March 21st. The shares were sold at an average price of $25.94, for a total transaction of $32,476.88. Following the sale, the insider now owns 21,515 shares in the company, valued at $558,099.10. The disclosure for this sale can be found here. Over the last quarter, insiders sold 6,360 shares of company stock worth $164,138. Corporate insiders own 29.00% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/08/adamas-pharmaceuticals-adms-forecasted-to-earn-q1-2018-earnings-of-1-41-per-share.html.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.